The company was founded in 2007. With its advantages in pharmaceutical process technology, the company also provides customized production services for key intermediates of new drugs, as well as the development and production of specialty pharmaceutical intermediates with complex chemical structures and high synthesis difficulties. On October 18, 2022, it successfully issued A-shares and was listed on the GEM. The company's main business mainly covers drug discovery (CRO), process research and development (CRO/CDMO), and commercial production (including CMO). The company's main products are drug discovery, including pharmaceutical chemistry research, synthetic chemistry research and pharmacokinetics research, process research and development, including process chemistry and process development, and CMC research for APIs, commercial production including customized production of new drugs (CMO), and R&D, production and sales of independent generic drug products.